Xenia Hotels & Resorts (XHR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Voting matters and shareholder proposals
Election of eight directors is proposed, with all nominees recommended for approval by the board.
Advisory vote on executive compensation is included, with board recommending approval.
Proposal to amend the 2015 Incentive Award Plan to increase the number of shares issuable, recommended for approval.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2025 is up for vote, with board support.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Eight director nominees are listed for election at the annual meeting.
Executive compensation and say-on-pay
Advisory, non-binding vote on executive compensation for named executive officers is on the agenda.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Xenia Hotels & Resorts
- Annual meeting features director elections, say-on-pay, and auditor ratification for 2026.XHR
Proxy filing31 Mar 2026 - Annual meeting covers director elections, say-on-pay, auditor ratification, and strong ESG focus.XHR
Proxy filing31 Mar 2026 - Double-digit earnings growth in 2025 with strong demand; 2026 outlook remains positive.XHR
Q4 202514 Mar 2026 - Net income up, EBITDAre down, and guidance trimmed as renovations and expense pressures persist.XHR
Q2 20242 Feb 2026 - Q3 loss and margin pressure offset by occupancy gains, strong group demand, and project completions.XHR
Q3 202415 Jan 2026 - 2025 guidance projects 3.5–6.5% RevPAR growth and $244–$264M Adjusted EBITDAre.XHR
Q4 202423 Dec 2025 - Annual meeting covers director elections, pay, equity plan, auditor, and strong governance.XHR
Proxy Filing2 Dec 2025 - Board seeks approval to expand equity awards, reinforcing pay-for-performance alignment.XHR
Proxy Filing2 Dec 2025 - Q1 2025 net income and RevPAR surged, but guidance was trimmed amid macro uncertainty.XHR
Q1 202528 Nov 2025